Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASCT Combined With BCMA CAR-T and GPRC5D/CD3 BiTEs in Primary Plasma Cell Leukemia
NCT07106684Phase 2Recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Aug 2025
- Primary completion
- Aug 2027
- Modality
- CAR-T Cells, Bispecific Antibodies, T-cell Engagers
- Countries
- 1
01
Overview
A Phase 2 trial of BCMA-CAR-T, GPRC5D/CD3 bispecific T-cell engager (Institute of Hematology & Blood Diseases Hospital) in plasma cell leukemia (PCL), sponsored by Institute of Hematology and Blood Diseases Hospital. Started Aug 2025; status: recruiting.
02
Drugs
BCMA-CAR-TGPRC5D/CD3 bispecific T-cell engager (Institute of Hematology & Blood Diseases Hospital)
03
Conditions
plasma cell leukemia (PCL)
Beyond the preview
Go deeper on NCT07106684.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07106684.